Use of illegally marketed slimming aids may carry significant health risks 26.08.2025 Swissmedic issues warning about the increasing number of falsified, misleading or unauthorised weight loss products currently on offer that make reference to GLP-1 active substances
MHRA GLP-1 Medicines: What You Need to Know (GOV.UK, 2026) The content on the SheMed blog is provided for general informational and educational purposes only
What are the different strengths of Semaglutide (Wegovy)
GLP-1s for Polyendocrine Metabolic Ovarian Syndrome Women with polyendocrine metabolic ovarian syndrome (PMOS) produce excess testosterone, which can lead to painful, heavy, or irregular periods, infertility, excess facial and body hair, severe acne, and small cysts on the ovaries
Individual results vary based on metabolism, diet, and activity level, with many patients losing 10-15 lbs in the first month and achieving a total loss of 20-50 lbs or more over time